In cell and mouse models, miR181a showed promise as a biomarker for early stage ovarian cancer and may help make immunotherapy treatment more effective.

Three early-stage cancer drug projects receive pilot grants to help them advance from the bench toward the bedside.

A new study sheds light on the risk of blood clots at all stages of ovarian cancer and the potential need for preventive blood thinners during pre-surgery chemotherapy.

The finding suggests a potential therapy to slow the disease in patients or a possible preventive strategy for women at high risk for ovarian cancer.

New research explains why this difficult-to-treat disease becomes resistant to chemotherapy, suggesting potential future treatment options.